ACADIA PharmaceuticalsMEX:ACAD 73 Gross Margin % is 90.75% as of Mar. 2026, which is 2% below its 10-year median of 93.02. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.71 (Fairly Valued). The stock has 9 warning signs investors should review. Among 736 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 85.87% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ACADIA Pharmaceuticals had a gross margin of 90.75% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ACADIA Pharmaceuticals Gross Margin % Related Terms
ACADIA Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ACAD vs EWTX, CRNX, VKTX: Gross Margin % Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ACADIA Pharmaceuticals (MEX:ACAD) has a Gross Margin % of 90.75% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ACADIA Pharmaceuticals and its competitors. This is near median its historical median of 93.02. Over the past decade, ACADIA Pharmaceuticals' Gross Margin % has ranged from 74.58 to 98.03. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #104 out of 736 companies in the Biotechnology industry, placing it in the top 14.1%.
Is ACADIA Pharmaceuticals' Gross Margin % too high?
ACADIA Pharmaceuticals' current Gross Margin % of 90.75% is near median its 10-year median of 93.02. Over the past 10 years, this metric has ranged from a low of 74.58 to a high of 98.03. The Biotechnology industry median Gross Margin % is 60.91. ACADIA Pharmaceuticals' value of 90.75% is 49% above this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #104 out of 736 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Gross Margin % compare to EWTX and CRNX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #104 out of 736 companies for Gross Margin %. This places ACADIA Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. ACADIA Pharmaceuticals' value of 90.75% is 49% above this benchmark. Historically, ACADIA Pharmaceuticals' own Gross Margin % has ranged from 74.58 to 98.03 over the past decade. While the company's 10-year median is 93.02 vs. the industry median of 60.91, ACADIA Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Gross Margin % of 90.75% is 49% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Gross Margin % is 90.75%, which is near median its own 10-year median of 93.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Gross Margin % is 90.75%, which is near median its 10-year median of 93.02 and 49% above the Biotechnology industry median of 60.91. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Gross Margin % is 90.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Gross Margin %: 90.75% (near median its 10-year median of 93.02)
GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
Industry Position: 49% above the Biotechnology median (#104 of 736)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
